Global Allergy Diagnostics and Therapeutics Market Size/Share Worth USD 78,036.1 Million by 2033 at a 8.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
18 nov. 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Allergy Diagnostics and Therapeutics Market Size, Trends and Insights By Product...
EAACI to Launch World Anaphylaxis Awareness Day on 21 November at FAAM-EUROBAT 2024
13 nov. 2024 05h43 HE
|
European Academy of Allergy and Clinical Immunology
On 21 November 2024, during the opening day of EAACI FAAM-EUROBAT 2024 in Athens, Greece, EAACI proudly launches World Anaphylaxis Day. Join us!
Insignis Therapeutics Receives Positive FDA Feedback on IN-001 Clinical Program for Needle-Free Anaphylaxis Treatment
05 nov. 2024 08h00 HE
|
Insignis Therapeutics, Inc.
Insignis Therapeutics advances IN-001, a needle-free anaphylaxis treatment, following FDA’s positive feedback and Fast Track designation.
EAACI Unveils Groundbreaking Guidelines for IgE-Mediated Food Allergy Management
30 oct. 2024 07h26 HE
|
European Academy of Allergy and Clinical Immunology
The European Academy of Allergy and Clinical Immunology (EAACI) has released updated "Clinical Guidelines on the Management of IgE-mediated Food Allergy."
Food Allergy Market Report 2024: $40+ Billion Industry to Grow at a CAGR of 6.7% During 2025-2030 - Innovations in Immunotherapy allergology Open New Avenues in Treatment
22 oct. 2024 09h00 HE
|
Research and Markets
Dublin, Oct. 22, 2024 (GLOBE NEWSWIRE) -- The "Global Food Allergy Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by Allergen Source, Treatment Type, Channel, Region, By...
Insignis Therapeutics Announces Positive Results from Phase 1 Clinical Study of IN-001 Liquid Epinephrine Sublingual Spray for Anaphylaxis
07 oct. 2024 08h00 HE
|
Insignis Therapeutics, Inc.
Insignis' Phase 1 trial shows IN-001 spray quickly reaches target epinephrine levels, sustained for 2 hours, offering a reliable needle-free alternative.
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
27 sept. 2024 09h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Certification to ISO 13485 extended to also include production process Supports Bentrio growth strategy together with strategic contract...
Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs
24 sept. 2024 04h00 HE
|
AKAMPION
Schlieren, Zurich/Switzerland, September 24, 2024 - Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has...
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
16 sept. 2024 08h30 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing...
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
23 août 2024 09h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Successful launch of Bentrio by Pharma Nordic AS in Norway in 2024Exclusive distribution agreement extended to also include Sweden and Denmark ...